Circassia’s product is a particle-engineered formulation of the inhaled long-acting muscarinic antagonist tiotropium bromide delivered via dry powder inhaler (DPI). The product targets direct substitution of Boehringer Ingelheim’s Spiriva® DPI, which is used in the treatment of chronic obstructive pulmonary disease.
Circassia completed early technical work on the particle-engineered formulation of tiotropium bromide and progressed the product into development targeting an abbreviated regulatory route. We subsequently completed manufacture of stability batches of our formulation in preparation for a pharmacokinetic clinical study.
Pipeline status: Spiriva® substitute